白介素1β基因多态性对质子泵抑制剂三联方案根除幽门螺杆菌疗效影响的Meta分析

Meta-analysis of Influence of Interleukin 1β Genetic Polymorphisms on Eradication of Helicobacter Pylori Infection with Proton Pump Inhibitors-based Triple Therapy

关键词:  白介素1β  基因多态性  质子泵抑制剂  幽门螺旋杆菌  meta分析

Key words:  interleukin 1β  genetic polymorphisms  proton pump inhibitors  Helicobacter pylori  meta-analysis

摘要:

目的 系统评价白介素1β（interleukin-1β，IL-1β）基因多态性与质子泵抑制剂三联方案根除幽门螺杆菌疗效的关系。方法 检索PubMed、Embase、CBM、CNKI、Wanfang data、CQVIP等数据库，收集IL-1β基因多态性（C-511T、T-31C）与质子泵抑制剂三联方案根除幽门螺杆菌感染的临床文献。根据纳入和排除标准筛选文献、评价和提取数据后，采用RevMan 5.3软件进行meta分析。结果 共纳入4篇文献，包含1 123例对象。Meta分析结果显示，IL-1β C-511T基因多态性中仅CC与TT基因型间质子泵抑制剂三联疗法的幽门螺杆菌根除率存在统计学差异（78.5%vs 92.1%，P<0.05）；CT与CC或TT基因型间幽门螺杆菌根除率无统计学差异（87.7%vs 78.5%，87.7%vs 92.1%）。IL-1β T-31C基因多态性中TT、TC与CC基因型间质子泵抑制剂三联疗法的幽门螺杆菌根除率无统计学差异（87.9%，84.6%，96.2%）。结论 IL-1β C-511T基因多态性可能影响质子泵抑制剂三联方案根除幽门螺杆菌的疗效。

Abstract:

OBJECTIVE To systematically review the influence of interleukin 1β(IL-1β) genetic polymorphisms C-511T or T-31C on eradication of Helicobacter pylori infection with proton pump inhibitors-based triple therapy.METHODS Such databases as PubMed, Embase, CBM, CNKI, Wanfang data and CQVIP were electronically searched for clinical studies on IL-1β genetic polymorphisms and proton pump inhibitors and Helicobacter pylori. According to the inclusion and exclusion criteria, literatures were screened, and data were extracted, and the methodologically quality of included studies were also examined. Meta-analysis were at last implemented using RevMan 5.3 software.RESULTS A total of 4 studies involving 1 123 patients were included. The results of meta-analysis showed that IL-1β genetic polymorphism C-511T of patients were significantly associated with successful eradication of Helicobacter pylori in the regiment of proton pump inhibitors-based triple therapy. Eradication rates for Helicobacter pylori in CC phenotype were remarkably lower than in TT phenotype (78.5% vs 92.1%, P<0.05). However, no significant eradication rates for Helicobacter pylori were observed between CT and CC or TT phenotypes (87.7% vs 78.5%, 87.7% vs 92.1%). IL-1β genetic polymorphism T-31C of patients were not associated with successful eradication of Helicobacter pylori in the treatment of proton pump inhibitors-based triple therapy.CONCLUSION IL-1β genetic polymorphism C-511T probably affects the efficacy of proton pump inhibitors-based triple therapy on the eradication of Helicobacter pylori infection.